We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

DIASOURCE

Develops, manufactures, and markets clinical diagnostic products that focus on endocrinology and infectious diseases read more Featured Products: More products

Download Mobile App




DIAsource ImmunoAssays SA Acquires Viro-Immun Diagnostics

By LabMedica International staff writers
Posted on 19 Sep 2017
DIAsource ImmunoAssays SA (Louvain-La-Neuve, Belgium), which develops, sells and distributes clinical diagnostics products, has acquired Viro-Immun Diagnostics GmbH (Viro-Immun Diagnostics GmbH), a developer and manufacturer of laboratory diagnostics for the medical diagnosis of infectious and autoimmune diseases.

DIAsource manufactures and sells manual kits and open automation for clinical diagnostics, while Viro-Immun offers a portfolio of assays in infectious and autoimmune diseases, including the ToRCH panel with parameters such as Toxoplasma, Rubella, Herpes. More...
With this transaction, DIAsource has acquired the Viro-Immun brand name and all ELISA and IFA products, as well as full inventory and infrastructure, thereby further strengthening and extending its portfolio of endocrinology and Vitamin D products. The acquisition of Viro-Immun fits in with DIAsource's strategy to act as a consolidator in its core business of manual kits and open automation.

Effective September 5, 2017, BioVendor - Laboratornímedicínaa.s. (Brno, Czech Republic) acquired 100% of the shares of DIAsource from Anteo Diagnostics (Queensland, Australia), which had acquired DIAsource in January 2016. The acquisition of DIAsource extended BioVendor’s broad panel of ELISA and RIA assays, antibodies and reagents for clinical diagnostics, as well as established a direct sales presence in Belgium, France and Spain, and a worldwide network of over 100 sales and distribution partners in over 70 countries.


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.